News

Dermatology Times has compiled a list of dermatological meetings taking place during the month of July.

At a recent Dermatology Times Case-Based Roundtable event, Andrew Baker, PA-C, MBA, explored the management of skin cancers with GEP testing through 4 complex cases.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Renata Block, DMSc, MMS, PA-C, interviews Andrew Baker, PA-C, MBA, to discuss his role as a sub-investigator in Castle Biosciences’ UTILISE study for cSCC.

Learn more about the in-depth topics covered in the June 2025 print issue of Dermatology Times.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

The FDA has accepted for review Allergan Aesthetics' sPMA for SKINVIVE by Juvéderm, seeking approval to treat neck lines.

Dermatology Times is looking back on the top stories in dermatology from the month of June.

Unlock exclusive insights from SDPA 2025 and get expert pearls, emerging data, and clinical strategies at your fingertips. Share with us to access the full recap.

Catch up on coverage from the fourth and final day of the 2025 SDPA Annual Summer Dermatology Conference held in Washington, DC.

Expert our review of the top pearls, clinical strategies, and practice-changing tips from leading voices in dermatology at SDPA’s 2025 Summer Conference.

Test your knowledge of key words, terms, and pearls associated with this weekend's SDPA Annual Summer Dermatology Conference.

From JAK inhibitors to trichoscopy and contact allergy clues, experts at SDPA 2025 shared their top clinical pearls for managing alopecia and hair loss.

A poster from SDPA 2025 showed brodalumab maintains a consistent safety profile with no completed suicides and low infection rates.

Eileen Cheever, MPAS, PA-C, highlights the growing role of JAK inhibitors in dermatology, including emerging data on prurigo nodularis and adolescent alopecia areata.

Maria Hordinsky, MD, urges dermatology clinicians to consider allergic contact dermatitis when scarring alopecia treatments fail.

Catch up on coverage from the third day of the 2025 SDPA Annual Summer Dermatology Conference held in Washington, DC.

At SDPA 2025, a poster evaluating the STRATUM trial showed roflumilast foam 0.3% effectively treats seborrheic dermatitis with minimal pigment changes.

David Cotter, MD, PhD, discusses diagnosing alopecia areata and selecting systemic treatments, including JAK inhibitors, from his SDPA 2025 presentation.

Amy Spizuoco, DO, FAOCD, shared how trichoscopy enhances alopecia evaluation by improving diagnostic speed, accuracy, and reducing biopsy need.

Nearly all injection site reactions among patients in the ARCADIA 1/2 and OLYMPIA 1/2 clinical trials were mild and transient in nature.

Ongoing maintenance therapy is essential to avoid relapse and preserve gains in repigmentation for patients with vitiligo, according to Gina Mangin, MPAS, PA-C.

Orit Markowitz, MD, shares how a color-focused strategy helps spot early malignancies—even 2-mm lesions—across all skin tones.

A yearlong study showed dupilumab alone effectively prevented flares in moderate to severe atopic dermatitis, with consistent safety across various dosing schedules.

Catch up on coverage from the second day of the 2025 SDPA Annual Summer Dermatology Conference held in Washington, DC.

Subcutaneous spesolimab maintained durable GPP control for 12 months after rapid clearance from IV spesolimab in a high-risk elderly patient.

Adam Friedman, MD, FAAD, outlines a stepwise approach to treating chronic hand eczema, from vehicle selection to systemic therapies and future innovations.

Orit Markowitz, MD, shares how her color wheel method boosts diagnostic clarity in dermoscopy by simplifying how clinicians assess benign lesions.

Quoin Pharmaceuticals advances QRX003 for Netherton Syndrome, receiving FDA's RPD Designation and showing promising clinical results.

A poster at SDPA highlights that dermatologists play a vital role in early detection of metastatic breast cancer, with skin changes often serving as the initial clue of internal disease recurrence.